The Bank of Montreal has significant holdings in Labcorp, worth $24.60 million, while Key Financial Inc and World Investment Advisors have recently bought positions in the company. However, there have been noteworthy stock sales by Labcorp's directors. These include an Independent Director selling 74% of his shares and Director Parham offloading stock worth $1.78m.
Labcorp’s Q3 earnings beat estimates, with a profit margin increase to 6.2% helping to boost investor confidence. There is speculation of upside growth with resilient margins and dividend support. The company is also celebrating the success of its newly launched FDA-cleared Alzheimer’s blood test.
Earnings statements from 2025 reflect a strong fiscal performance, attracting new investors such as Rep. April McClain Delaney and Atlantic Union Bankshares Corp. Despite occasional setbacks, including a stock price drop, Labcorp continues to leverage its innovation, particularly in the digital pathology partnership with Roche and Diagnostic Growth initiatives.
Labcorp's acquisition of select BioReference Health assets signifies an expansion of its innovative oncology and clinical testing services. However, the selling off of US$8.7m in stock by insiders may point towards potential future weaknesses.
Laboratory Corporation of America Holdings LH News Analytics from Thu, 06 Feb 2025 08:00:00 GMT to Sat, 08 Nov 2025 09:02:42 GMT - Rating 7 - Innovation 6 - Information 8 - Rumor 2
